Cover Image
市場調查報告書

非專利固態劑:產品、市場、企業、展望

Generic Solid Dosage Forms: Products, Markets, Players and Outlook

出版商 Greystone Research Associates 商品編碼 395940
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
非專利固態劑:產品、市場、企業、展望 Generic Solid Dosage Forms: Products, Markets, Players and Outlook
出版日期: 2016年11月18日 內容資訊: 英文
簡介

本報告提供固態劑型的學名藥的市場調查,學名藥的經濟學,市場機會及市場成長及需求擴大的推動因素分析,ANDA申請策略的重要性,主要供應商的存在感及產品的地位分析,各治療層級、藥物類別、適應症分析等彙整資料。

摘要整理

市場機會

  • 學名藥的經濟學
  • 學名藥的成長
  • 需求推動因素
  • 競爭環境

非專利固態劑:成長因素

  • 專利和獨佔銷售權
  • 訴訟和FTF (First-to-File) ANDA策略
  • ANDA的買賣

非專利固態劑:產品相關的考察

  • 製劑因素
  • 放出性調整
    • 緩釋性
    • 遲放性
  • 特殊服用形態
    • 咀嚼錠
    • 溶解性製劑

非專利固態劑:市場分析

  • 各治療層級分析
    • 成癮
    • 抗感染疾病
    • 解痙藥
    • 抗病毒
    • 心臟
    • 皮膚
    • 內分泌系
    • 消化器官系統
    • 免疫系
    • 感染疾病
    • 代謝系
    • 腎臟系
    • 神經系統
    • NSAID
    • 腫瘤
    • 眼科
    • 骨質疏鬆症
    • 抑制劑
    • 疼痛管理
    • 生殖健康
    • 上呼吸道發炎
    • 泌尿器官系統
  • 各類藥物
    • 超越80種類分析
  • 各適應症
    • 超越30種的各適應症分析

市場影響因素

  • 法律規章上的課題
  • 訴訟相關的課題
  • ANDA申請策略的演進
  • CMO所扮演的角色
  • 醫療經濟學

企業分析

目錄
Product Code: SDF922K

The generic solid dosage form drug segment is a rapidly evolving and highly unpredictable environment that has been a challenge to decision makers attempting to map strategies for success in this segment. There are 597 distinct APIs for which there is at least one approved generic solid dosage form ANDA. These 597 APIs account for 4,229 approved ANDAs. Including all approved doses, the current universe of generic solid dosage forms consists of 9,687 unique tablet and capsule products. These products are marketed and supplied by more than 800 companies. Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.

Generic Solid Dosage Forms - What You Will Learn

  • Provides detailed analysis of generic drugs supplied as solid dosage forms and assesses key market segments, market dynamics and potential product opportunities
  • Presents the competitive picture for generic tablets and capsules in two dozen drug classes
  • Evaluates the importance of ANDA filing strategies and indirect ANDA acquisition on participant growth prospects
  • Analyzes the impact of patents, exclusivity and litigation on participant market sector prospects
  • Assesses the market presence and product position of the top twenty-four generic suppliers in the solid dosage form segment
  • Evaluates the impact of economic, technology, and regulatory factors

Table of Contents

Executive Summary

The Market Opportunity

  • The Economics of Generic Drugs
  • Growth in Generics
  • Demand Drivers
  • Competitive Landscape

Generic Solid Dosage Forms - Growth Factors

  • Patents and Exclusivity
  • Litigation and First-to-File ANDA Strategies
  • Buying and Selling ANDAs

Generic SDFs - Product Considerations

  • Formulation Factors
  • Modified Release
    • Extended Release
    • Delayed Release
  • Specialty Dosage Forms
    • Chewable Tablets
    • Dissolvable Dosage Forms

Generic Solid Dosage Forms - Market Analysis

Therapeutic Class Analysis

  • Addiction
  • Anti-Infective
  • Antispasmodic
  • Antiviral
  • Cardiology
  • Dermatology
  • Endocrinology
  • Gastroenterology
  • Immunology
  • Infectious Disease
  • Metabolic
  • Nephrology
  • Neurology
  • NSAIDs
  • Oncology
  • Ophthalmology
  • Osteoporosis
  • Inhibitors
  • Pain Management
  • Reproductive Health
  • Upper Airway Diseases
  • Urology

Drug Classes

Includes more than eighty drug classes

Indications

Analyzes more than three dozen market segments

Market Factors

  • Regulatory Issues
  • Litigation Issues
  • Evolving ANDA Filing Strategies
  • The Role of CMOs
  • Healthcare Economics

Company Analysis

Back to Top